<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01101152</url>
  </required_header>
  <id_info>
    <org_study_id>REB-2009036</org_study_id>
    <nct_id>NCT01101152</nct_id>
  </id_info>
  <brief_title>Effectiveness of the Dual Serotonin Norepinephrine Reuptake Inhibitor Desvenlafaxine Succinate in Healthy Volunteers</brief_title>
  <acronym>DVS</acronym>
  <official_title>Effectiveness of the Dual Serotonin Norepinephrine Reuptake Inhibitor Desvenlafaxine Succinate in Healthy Females and Males</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ottawa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Ottawa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      DVS is the main metabolite of the antidepressant/anxiolytic medication Venlafaxine (Effexor).
      Like parent compound, DVS is an antidepressant inhibiting both serotonin (5-HT) and
      norepinephrine (NE) reuptake. However, no studies to date describe the in vivo potency of
      this drug on monoamines reuptake. Consequently, it appears essential to determine the potency
      of DVS in human subjects using a wide dose range in order to determine at which dose(s) it
      starts inhibiting 5-HT and NE reuptake. The investigators are interested in learning whether
      there is a gender difference in the dose of the study medication at which NE reuptake
      inhibition occurs.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The degree of norepinephrine reuptake in response to the increasing levels of the study medication will be assessed and compared between genders</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The degree of serotonin reuptake in response to the increasing levels of the study medication will be assessed and compared between genders</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Female</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Male</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desvenlafaxine succinate</intervention_name>
    <description>Tablets of 50 mg,100 mg; Dosing regimen: 50, 100, 200 mg/day; 1 week for each dose regimen;
1 tablet a day for doses of 50 and 100mg/day, and 2 tablets of 100mg for dose of 200mg/day</description>
    <arm_group_label>Female</arm_group_label>
    <arm_group_label>Male</arm_group_label>
    <other_name>Pristiq</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female subjects between 18 and 40 years of age, including those on oral contraceptive
             pills

          -  Male subjects between 18-40 years of age

          -  Written informed consent signed by the subject.

        Exclusion Criteria:

          -  Life-time personal history of diagnosis of major depression according to the DSM-IV
             (American Psychiatry Association, 1994) using the MINI (Sheehan et al. 1998)

          -  Blood pressure greater than 140/90 and a pulse rate greater than 90bpm

          -  Evidence of significant physical illness contraindicating the use of DVS, found on
             physical or in the laboratory data obtained during the first week of the study

          -  Obvious mental retardation rendering the response to investigators unreliable

          -  Pregnancy, or absence of adequate contraceptive method.

          -  Concurrent use of psychotropic medication such as antipsychotics, mood stabilizers or
             regular use of benzodiazepines.

          -  Participation in a clinical trial within 30 days of entry into the current study

          -  Intolerance to Desvenlafaxine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Blier, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Ottawa Institute of Mental Health Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olga Chernoloz, B.Sc.Pharm</last_name>
    <phone>613-722-6521</phone>
    <phone_ext>6405</phone_ext>
    <email>olga.chernoloz@rohcg.on.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wendy Fusee, RN</last_name>
    <phone>613-722-6521</phone>
    <email>wendy.fusee@rohcg.on.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Ottawa Institute of Mental Health Research</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Z 7K4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Chernoloz, B.Sc.Pharm</last_name>
      <phone>613-722-6521</phone>
      <phone_ext>6405</phone_ext>
      <email>olga.chernoloz@rohcg.on.ca</email>
    </contact>
    <investigator>
      <last_name>Pierre Blier, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.imhr.ca</url>
    <description>University of Ottawa Institute of Mental Health Research homepage</description>
  </link>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2010</study_first_submitted>
  <study_first_submitted_qc>April 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2010</study_first_posted>
  <last_update_submitted>August 4, 2011</last_update_submitted>
  <last_update_submitted_qc>August 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Pierre Blier, MD, Ph.D.</name_title>
    <organization>University of Ottawa Institute of Mental Health Research</organization>
  </responsible_party>
  <keyword>Antidepressant</keyword>
  <keyword>healthy volunteers</keyword>
  <keyword>desvenlafaxine succinate</keyword>
  <keyword>norepinephrine reuptake</keyword>
  <keyword>serotonin reuptake</keyword>
  <keyword>tyramine test</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Serotonin</mesh_term>
    <mesh_term>Norepinephrine</mesh_term>
    <mesh_term>Desvenlafaxine Succinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

